I'm LongbridgeAI, I can summarize articles.Citius Pharmaceuticals reported FY26 Q3 revenue of $1.49 million, up from zero last year, while net loss narrowed to $8.86 million ($0.34/share) from $8.79 million. Cash reserves increased to $17.01 million. LYMPHIR is now available at 44 institutions, with wholesale orders rising 31% and new ordering sites up 80%. Management confirmed near-universal payer coverage with no reimbursement denials.
- Citius Pharmaceuticals posted revenue of USD 1.49 million for the quarter, versus no revenue a year earlier. * Net loss applicable to common stockholders narrowed to USD 8.86 million, or USD 0.34 per share, from USD 8.79 million, or USD 0.80. * Cash and cash equivalents rose to USD 17.01 million at June 30, 2026, from USD 4.25 million at Sept. 30, 2025. * LYMPHIR became available at 44 institutions; institutional vial orders from wholesalers rose 31% as new ordering institutions increased 80%. * Management said near-universal payer coverage has been secured, with no reimbursement denials or preauthorization barriers reported to date. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608141630PR_NEWS_USPR_____NE26853) on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)